α4β2* Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease Gait-Balance Disorders.

Roger L AlbinMartijn L T M MüllerNicolaas I BohnenCathie SpinoMartin SarterRobert A KoeppeAshley SzparaKamin KimCindy LustigWilliam T Dauer

Published in: Annals of neurology (2021)

Varenicline occupied α4β2* nicotinic acetylcholine receptors, was tolerated well, enhanced attention, and altered gait performance. These results are consistent with target engagement. α4β2* agonists may be worth further evaluation for mitigation of gait and balance disorders in PD. ANN NEUROL 2021;90:130-142.

Keyphrases

parkinson disease
cerebral palsy
deep brain stimulation
social media
climate change
working memory
smoking cessation
binding protein
neural network